Literature DB >> 1458665

Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly.

D Reinel1, C Clarke.   

Abstract

Amorolfine is a new topical antifungal of the phenylpropyl morpholine class which is highly active both in vitro and in vivo against yeasts, dermatophytes and moulds responsible for superficial fungal infections. Human pharmacological studies have established that amorolfine has a persistent antifungal effect in the nail bed and in the skin without being systemically absorbed. This has been confirmed by clinical work showing that amorolfine is effective in treating dermatomycoses and onychomycoses when administered as cream or nail lacquer. It is ineffective when given orally for systemic mycoses or bacterial infections in animals. In earlier studies a 5% concentration of amorolfine nail lacquer was found to produce a better cure rate in onychomycosis than a lower concentration of 2%. From data available on the penetration of amorolfine and on the persistence of mycologically relevant tissue concentrations, it appeared likely that once- or twice-weekly application of nail lacquer should suffice to produce a satisfactory therapeutic effect in onychomycosis. The aim of this investigation was to assess the efficacy and tolerability of 5% amorolfine nail lacquer given once versus twice weekly to patients with onychomycosis of finger nails and toe nails.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458665     DOI: 10.1111/j.1365-2230.1992.tb00278.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  14 in total

1.  Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.

Authors:  Tsuyoshi Shimamura; Nobuo Kubota; Saori Nagasaka; Taku Suzuki; Hideki Mukai; Kazutoshi Shibuya
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

Review 2.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 3.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Pharmacoeconomic analysis of topical treatments for tinea infections.

Authors:  N H Shear; T R Einarson; S R Arikian; J J Doyle
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

5.  Ciclopirox 8% HPCH Nail Lacquer in the Treatment of Mild-to-Moderate Onychomycosis: A Randomized, Double-Blind Amorolfine Controlled Study Using a Blinded Evaluator.

Authors:  Matilde Iorizzo; Ilona Hartmane; Andra Derveniece; Ingmars Mikazans
Journal:  Skin Appendage Disord       Date:  2015-11-07

Review 6.  Onychomycosis in the elderly : drug treatment options.

Authors:  Daniel S Loo
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  Management of onychomycoses.

Authors:  M Niewerth; H C Korting
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 8.  Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

Authors:  M Haria; H M Bryson
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

9.  Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group.

Authors:  M Bräutigam; S Nolting; R E Schopf; G Weidinger
Journal:  BMJ       Date:  1995-10-07

Review 10.  Topical treatments for fungal infections of the skin and nails of the foot.

Authors:  F Crawford; S Hollis
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.